In this episode of It Takes Balls, Dr. Darren Feldman, a genitourinary medical oncologist at Memorial Sloan Kettering Cancer Center, provides a deep, evidence-based conversation on testicular cancer treatment, chemotherapy decision-making, and long-term survivorship. Dr. Feldman breaks down how cisplatin transformed testicular cancer from a fatal disease into one of the most curable solid tumors, even in cases of metastatic disease.

The discussion explores the differences between BEP, EP, VIP, and TIP chemotherapy regimens, including when and why each is used, how doctors balance cure rates with toxicity, and why lung health, kidney function, age, and patient goals matter when choosing treatment. Dr. Feldman also explains why cisplatin remains superior to carboplatin in advanced germ cell tumors, when surveillance is preferred over treatment in stage 1 disease, and how overtreatment can carry long-term risks.

Later in the episode, Dr. Feldman addresses common patient concerns around recurrence risk, radiation vs surveillance, retroperitoneal lymph node dissection (RPLND), testosterone changes after chemotherapy, and misinformation surrounding alternative therapies.

Provide your feedback on the podcast:

https://www.testicularcancerawarenessfoundation.org/itbsurvey

Have a question for a future expert guest? Submit here:

https://www.testicularcancerawarenessfoundation.org/it-takes-balls-question-submission

Want to be a guest? Apply here:

https://www.testicularcancerawarenessfoundation.org/it-takes-balls-submissions

Follow Testicular Cancer Awareness Foundation:

⁠https://www.testescancer.org

https://www.twitter.com/testescancer⁠

⁠https://www.instagram.com/testescancer

https://www.facebook.com/tca.org

Dr. Feldman:

https://www.mskcc.org/cancer-care/doctors/darren-feldman

Follow Steven Crocker:

https://www.instagram.com/stevencrocker

https://www.facebook.com/steven.crocker2

Theme song: No Time Like Now - Tom Willner www.tomwillner.com